EMA To Add New Side Effects To Janssen, AstraZeneca COVID-19 Shots - AstraZeneca (NASDAQ:AZN), Johnson & Johnson (NYSE:JNJ)

The European Medicines Agency (EMA) has finalized to update the product information of COVID-19 vaccines developed by Johnson & Johnson JNJ and AstraZeneca plc AZN to reflect several newly detected side effects.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has finalized the updates to the product information of J&J’s (JNJ) single-dose shot to indicate “swollen lymph nodes, unusual or decreased feeling in the skin, tinnitus, diarrhea, and vomiting,” as potential side effects.
EMA said that for AstraZeneca’s vaccine, the product information would be updated to reflect Guillain-Barré syndrome (GBS) as a side effect.
Related Content: European Medicine Agency Lists Guillain-Barré Syndrome As Rare Side Effect For JNJ COVID-19 Vaccine.
Price Action: JNJ shares are down 0.20% at $172 during the market session on the last check Wednesday.
Photo by Johaehn from Pixabay